Clinical Trials
3 trialsNCT03976323 2026-02-25
Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03976362 2026-02-25
KEYLYNK-008
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04566952 2020-10-30
ANLOLA
Jiangsu Cancer Institute & Hospital
Phase 2 Unknown